Distinct Baseline Molecular Endotypes but Convergent Responses to Ustekinumab in Psoriatic Arthritis: Longitudinal Multi-Omics Analyses from the Randomised MUST Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2946; Pres time: Nov 11, 2026; 10:45 AM - 11:00 AM; Location: W415D; In Person; P3 | "PsA is characterized by distinct sex-associated molecular endotypes at baseline. Despite these differences, ustekinumab induced largely convergent molecular responses across sexes, suggesting that sex-related differences in clinical outcomes may reflect baseline disease biology rather than differential pharmacodynamic effects. Pathways associated with super-response may represent candidate mechanisms for treatment stratification and precision medicine approaches in PsA."
Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|
|
Michaela Koehm1; Anke Koenig2; Michael Teske1; Robert Gurke1; Thomas Oellerich2; Gerd Geißlinger1; Frank Behrens1
|